LXEO Lexeo Therapeutics
- 9.560
- -0.030-0.31%
- 9.560
- 0.0000.00%
Lexeo Therapeutics News
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Townsend Richard Nolan
Lexeo Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Townsend Richard Nolan
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 10-Q: Q2 2024 Earnings Report
Lexeo Therapeutics | 8-K: Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Eventide Asset Management, LLC(6.65%),Finny Kuruvilla, M.D. Ph. D.(6.65%), etc.
Lexeo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(10.3%),Janus Henderson Biotech Innovation Master Fund Ltd(5.1%)
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 8-K: Current report
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Townsend Richard Nolan
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Van Hauwermeiren Timothy
Lexeo Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Van Hauwermeiren Timothy
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 8-K: Current report
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 8-K: Current report
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director COOPERSTONE BRENDA
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Altschuler Steven
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director DIAZ REINALDO M
Analysis
Price Target
No Data
No Data